Pancreatic response to gold nanoparticles includes decrease of oxidative stress and inflammation in autistic diabetic model

Cellular Physiology and Biochemistry

Volumn 35, Issue 2, 2015, Pages 586-600

  Selim, Manar E ^a   Abd Elhakim, Yasmina M ^b   Al Ayadhi, Laila Y ^c  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b Zagazig University   (Egypt)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Antioxidant; AuNPs; Autism; ORAC

Indexed keywords

AMINOTRANSFERASE; CATALASE; CREATININE; GLUCOSE; GLUTATHIONE PEROXIDASE; GLYCOGEN; GOLD NANOPARTICLE; HYDROCORTISONE; SEROTONIN; STREPTOZOCIN; SUPEROXIDE DISMUTASE; UREA; VALPROIC ACID; ANTIOXIDANT; GOLD; METAL NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ANTIOXIDANT ASSAY; ARTICLE; AUTISM; BODY FAT; CELL NUCLEUS; CELL NUCLEUS MEMBRANE; CONCENTRATION (PARAMETERS); CONCEPTION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIET RESTRICTION; ENZYME ACTIVITY; EUCHROMATIN; FEMALE; GLUCOSE BLOOD LEVEL; HYDROCORTISONE BLOOD LEVEL; INFLAMMATION; KIDNEY FUNCTION; LIPID PEROXIDATION; LIVER; MALE; NONHUMAN; ORAC ASSAY; OXIDATIVE STRESS; PANCREAS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; SEROTONIN BLOOD LEVEL; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRANSMISSION ELECTRON MICROSCOPY; UREA NITROGEN BLOOD LEVEL; ANIMAL; AUTISTIC DISORDER; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; PATHOPHYSIOLOGY; WISTAR RAT;

RATTUS;

ANIMALS; ANTIOXIDANTS; AUTISTIC DISORDER; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; GOLD; LIPID PEROXIDATION; MALE; METAL NANOPARTICLES; OXIDATIVE STRESS; PANCREAS; RATS; RATS, WISTAR; VALPROIC ACID;

EID: 84921875047     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000369721     Document Type: Article

References (78)

1. Palmieri L, Persico AM: Mitochondrial dysfunction in autismspectrum disorDers: cause or effect? Biochim Biophys Acta 2011; 1797: 1130-1137.
2. Villagonzalo KA, Dodd S, Dean 0, Gray K, Tonge B, Berk M: Oxidative pathways as a drug target for the treatment of autism. Expert Opin Ther Targets 2010, 14: 1301-1310.
3. Ghanizadeh A: Oxidative stress may mediate association o f stereotypy and immunity in autism, a novel explanation withclinical and research implications. J Neuroimmunol 2011, 23 2: 194-195.
4. Meguid NA, Dardir AA, Abdel-Raouf ER, Hashish A: Evaluation of oxidative stress in autism: defective antioxidantenzymes and increased lipid peroxidation. Biol Trace Elem Res 2011, 143: 58-65.
5. Mostafa GA, El-Hadidi ES, Hewedi DH, Abdou MM: Oxidative stress in Egyptian children with autism: relation toautoimmunity. J Neuroimmunol 2010; 219: 114-118.
6. Krajcovicova-Kudlackova M, Valachovicova M, Mislanova C, Hudecova Z, Sustrova M, Ostatnikova D: Plasma concentrations of selected antioxidants in autistic children and adolescents. Bratisl. Lek Listy 2 00 9410: 2 47-25 0.
7. Leonard H, De-Klerk N, Bourke L Bower C: Maternal health in pregnancy and intellectual disability in the offspring: a population-based study. Mn Epidemiol 200646: 448-454.
8. Wilkerson DS, Volpe AG, Dean RS, Titus JB: Perinatal complications as predictors of infantile autism. Int Neurosci 2002412: 1085-1098.
9. Krakowiak P, Walker CK, Bremer AA, Baker AS, Ozonoff S, Hansen RL, Hertz-Picciotto I: Maternal metabolic conditions and risk for autism and other neurodevelopmental disorDers. Pediatrics 2012; 129: e1121-e1128.
10. Gardener H, Spiegelman D, Buka SL: Prenatal risk factors for autism: comprehensive meta-analysis. Br Psychiatry 2009495: 7-14.
11. Reynolds RM: Glucocorticoid excess and the developmental origins of disease: two decades of testing the hypothesis-201 2 Curt Richter award Winner Psychoneuroendocrinology 2 013; 38 : 1-11.
12. Cowen PJ: Cortisol, serotonin and depression: all stressed out? Brit J Psychiatry 2002480: 99-100.
13. Gabbe SG: Gestational diabetes mellitus. N Engl J Med 1986; 315: 1025-1026.
14. American Diabetes Association: Gestational diabetes mellitus. Diabetes Care 2004; 27: 588-590.
15. Ahmed SA, Shalayel MH: Role of cortisol in the deterioration of glucose tolerance in Sudanese pregnant women. East Afr Med J 1999; 76: 465-467.
16. Zhang C, Ning Y: Effect of dietary and lifestyle factors on the risk of gestational diabetes: review of epidemiologic evidence. Am J Clin Nutr 2011; 94: 19755-19795.
17. Kuhl C: Glucose metabolism during and after pregnancy in normal and gestational diabetic women. 1. Influence of normal pregnancy on serum glucose and insulin concentration during basal fasting conditions and after a challenge with glucose. Acta Endocrinol (Copenhj 1975; 79: 709-719.
18. Buchanan TA, Xiang AH: Gestational diabetes mellitus. J Clin Invest 2005, 115: 485-491.
19. Ornoy A: Prenatal origin of obesity and their complications: gestational diabetes, maternal overweight and the paradoxical effects of fetal growth restriction and macrosomia. Reprod Toxicol 2011; 32: 205-212.
20. Urizar GG Jr, Munoz RF: Impact of a prenatal cognitive-behavioral stress management intervention on salivary cortisol levels in low-income mothers and their infants. Psychoneuroendocrinology 2011; 36: 1480-1494.
21. Seckl JR, Holmes MC: Mechanisms of disease: glucocorticoids, their placental metabolism and fetal 'programming' of adult pathophysiology. Nat Clin Pract Endocrinol Metab 2 007; 3 : 479-488.
22. Beitins IZ, Bayard F, Ances IG, Kowarski A, Migeon CJ: The metabolic clearance rate, blood production, interconversion and transplacental passage of cortisol and cortisone in pregnancy near term. Pediatr Res 1973; 7: 509-519.
23. Pinto-Martin JA, Levy SE, Feldman JF, Lorenz JM, Paneth N, Whitaker AH: Prevalence of autism spectrum disorDer in adolescents born weighing < 2000 grams. Pediatrics 2011428: 883-891
24. Clifton VL, Murphy VE: Maternal asthma as a model for examining fetal sex-specific effects on maternal physiology and placental mechanisms that regulate human fetal growth. Placenta 2004; 25: S45-52.
25. Binkerd PE, Rowland JM, Nan H, Hendricks AG: Evaluation of valproic acid (VPAJ developmental toxicity and pharmacokinetics in Sprague-Dawley rats. Fundam Appl Toxicol 198841: 485-493.
26. Ito M, Kondo Y, Nakatani A, Naruse A: New model of progressive non-insulin-dependent diabetes mellitus in mice induced by streptozotocin. Biol Pharm Bull 1999; 22: 988-989.
27. Selvaraj B, Kalimuthu K, Muthuirulappan 5, SureshBabu R, Hyung-seop Y, SooHyun E, Sangiliyandi G: Anti-oxidant effect of gold nanoparticles restrains hyperglycemic conditions in diabetic mice. Nanobiotechnology 2010; 8: 16.
28. Cao G, Booth SL, Sadowski JA, Prior RL: Increases in human plasma antioxidant capacity after consumption of controlled diets high in fruit and vegetables. Am J Clin Nutr 1998; 68 : 1081-1087.
29. Spitz DR, Oberley LW: An assay for superoxide dismutase activity inmammalian tissue homogenates. Anal Biochem 1989; 179: 8-18.
30. Flohe L, Gunzler WA: Assays of glutathione peroxidase. Methods Enzymoll984; 105: 114-119.
31. Aebi H: Catalase in vitro. Methods Enzymol 1984405: 121-127.
32. Tietze F: Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 1969; 27: 502-522.
33. Tappel AL, Zalkin H: Inhibition of lipide peroxidation in mitochondria by vitamin E. Arch Biochim Biophys 1959; 80: 333-336.
34. Bligh EG, Dyer WJ: A rapid method of lipid extraction and purification. CanJBiochem Phsioll9S9; 37: 911-917.
35. Gottfried SP, Rosenberg B: Improved manual spectrophotometric procedure for determination of serum triglycerides. Clin Chem 197349: 1077-1078.
36. Zlatkis A, Zak B, Boyle AJ: Anewmethod for the direct determination of serum cholesterol. J Lab Clin Med 195 3; 41: 486-492.
37. Calzyme Laboratories [http://www.calzyme.com/catalog/acidphos.htmlj
38. Calam RR: Specimen processing separator gels: an update. J Clin Immunoassay 198841: 86-90.
39. Gire P: Contribution a 1'6tude du determinisme des viandes a coupe sombre chez le mouton: 'facteurs de mobilisation du glycogène musculaire pendant le stress de transport. Th. 3e; Cycle, Clermont-Ferrand, 1976, 147 pp.
40. Dalle M, Delost P: Plasma and adrenal cortisol concentrations in foetal, newborn and mother guinea-pigs during the perinatal period. J Endocrinol 1976; 70: 207-214.
41. Kluge H, Bolle M, Reuter R, Werner 5, Zahlten W, Prudlo J: Serotonin in platelets: comparative Analyses using New enzyme immunoassay and HPLC Test Kits and the traditional fluorimetric procedure. J Lab Med 199 9; 2 3 : 36 0-3 64.
42. Lasagna-Reeves C, Gonzalez-Romero D, Barria MA, Olmedo I, Cbs A, Sadagopa Ramanujam VM, Urayama A, Vergara L, Kogan MJ, Soto C: Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. Biochem Biophys Res Commun 2010; 393: 649-655.
43. Zhang XD, Wu HY, Wu D, Wang YY, Chang JH, Zhai ZB, Meng AM, Liu PX, Zhang LA, Fan FY: Toxicologic effects of gold nanoparticles in vivo by different administration routes. Int j Nanomedicine 2010; 5: 771-781.
44. Tedesco 5, Doyle H, Blasco L Redmond G, Sheehan D: Oxidative stress and toxicity of gold nanoparticles in Mytilus edulis. Aquat Toxicol 2010400: 178-186.
45. Tsoli M, Kuhn H, Brandau W, Esche H, Schmid G: Cellular uptake and toxicity ofAuSS clusters. Small 20054: 841-844.
46. Zidki H, Cohen D, Meyerstein L: Reactions of alkyl-radicals with gold and silver nanoparticles in aqueous solution Phys. Chemistry Chem Phys 2000; 8: 3552-3556.
47. ZhangAB, LeVanon H, Fessenden RW, Meisel D: On the interactions of free radicals with gold nanoparticles. JAm Chem Soc 2003425: 7959-7963.
48. Barathmanikanth S, Kalishwaralal K, Sriram M, Pandian SR, Youn HS, Eom S, Gurunathan S: Anti-oxidant effect of gold nanoparticles restrains hyperglycemic conditions in diabetic mice. J Nanobiotechnol 2010; 8: 16.
49. Carlo MD, Loeser RF: Increased oxidative stress with aging reduces chondrocytesurvival: correlation with intracellular glutathione levels. Arthritis Rheum 2 003; 48 : 3419-3430.
50. James SJ, Melnyk 5, Jernigan 5, Cleves MA, Halsted CH, Wong DL Cutler P, Bock K, Boris M, Bradstreet JJ, Baker SM, Gaylor DW: Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet 2006; 141B: 947-956.
51. Droge W: Free radicals in the physiological control of cell function. Physiol Rev 2002; 82 : 47-95.
52. Ghanizadeh A: Malondialdehyde, Bcl-2, superoxide dismutase and glutathione peroxidase may mediate the association of sonic hedgehog protein and oxidative stress in autism. Neurochem Res 2012; 37: 899-901.
53. Meguid NA, Dardir AA, Abdel-Raouf ER, Hashish A: Evaluation of oxidative stress in autism: defective antioxidant enzymes and increased lipid peroxidation. Biol Trace Elem Res 2011443: 58-65.
54. Malik M, Sheikh AM, Wen G, Spivack W, Brown WT, Li X: Expression of inflammatory cytokines, Bc12 and cathepsin Dare altered in lymphoblasts of autistic subjects. Immunobiology 2011; 216: 80-85.
55. El-Ansary A, Al-Daihan 5, Al-Dbass A, Al-Ayadhi L: Measurement of selected ions related to oxidative stress and energy metabolism in Saudi autistic children. Clin Biochem 2010; 43: 63-70.
56. Sauer H, Wartenberg M, Hescheler J: Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem 200141: 173-186.
57. Lim SI, Zhong CJ: Molecularly mediated processing and assembly of nanoparticles: exploring the interparticle interactions and structures. Acc Chem Res 2009; 42: 798-808.
58. Van Dam PS, Van Asbeck BS, Erkelens DW, Marx JJM, Gispen WH, Bravenboer B: The role of oxidative stress in neuropathy and other diabetic complications. Diabetes Metab Rev 199541: 181-192.
59. Wolff SP: Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br Med Bull 1993; 49: 642-652.
60. Yan SD, Schmidt AM, AnDerson GM, Zhang L Brett L Zou YS, Pinsky D, Stern D: Enhanced cellular oxidative stress by the interaction of adVanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-9897.
61. Maziere C, Auclair M, Rose-Robert F, Leflon P, Maziere JC: Glucose-enriched medium enhances cell-mediated low density lipoprotein peroxidation. FEBS Lett 1995; 363: 277-279.
62. Singha 5, BhattacharyaJ, Datta H, DasguptaAK: Anti-glycation activity of gold nanoparticles. Nanomedicine 2 00 9; 5 : 2 1-2 9.
63. Paulmann N, Grohmann M, Voigt JP, Bert B, Vowinckel L BaDer M, Skelin M, Jevsek M, Fink H, Rupnik M, Walther DJ: Intracellular serotonin modulates insulin secretion from pancreatic beta-cells by protein serotonylation.PLoS. Biologicals 2009; 7: e10002 29.
64. Chandana SR, Behen ME, Juhasz C, Muzik 0, Rothermel RD, Mangner TL Chakraborty PK, Chugani HT, Chugani DC: Significance of abnormalities in developmental trajectory and asymmetry of cortical serotonin synthesis in autism. Int J Dev Neurosci 2005; 23: 171-182.
65. Chugani DC: Role of altered brain serotonin mechanisms in autism. Mol Psychiatry 2002; 7: 516-517.
66. Arafah BM: Hypothalamic pituitary adrenal function during critical illness: limitations of current assessment methods. J din EndocrinolMetab 2006; 91: 3725-3745.
67. Murphy DL Fox MA, Timpano KR, Moya PR, Ren-Patterson R, Andrews AM, Holmes A, Lesch KP, Wendland JR: How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems. Neuropharmacology 2008; 55: 932-960.
68. Connor EE, Mwamuka J, Gole A, Murphy CL Wyatt MD: Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small 20054: 325-327.
69. Dani RK, Kang M, Kalita M, Smith PE, Bossmann SH, Chikan V: MspA porin-gold nanoparticle assemblies: enhanced binding through a controlled cysteine mutation. Nano Lett. 2008; 8: 1229-1236.
70. Fecteau 5, Mottron L, Berthiaume C, Burack JA: Developmental changes of autistic symptoms. Autism 2003; 7: 255-268.
71. EVans JL, Goldfine ID, Maddux BA, Grodsky GM: Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 2003; 52: 1-8.
72. Robertson RP: Oxidative stress and impaired insulin secretion in type 2 diabetes. Curr Opin Pharmacol 2006; 6: 615-619.
73. Korshunov SS, Skulachev VP, StarkovAA: High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Lett. 1997; 416: 15-18.
74. Degirmenci I, Ustuner MC, KalenDer Y, KalenDer 5, Gunes HV: The effects of acarbose and Rumex patientia L. On ultrastructural and biochemical changes of pancreatic b cells in streptozotocin-induced diabetic rats. J Ethnopharmacol 2005; 97: 555-559.
75. Tyrberg B, AnDersson A, Borg LA: Species differences in susceptibility of transplanted and cultured pancreatic islets to the b-cell toxin alloxan. Gen Comp Endocrinol 2001422, 238-251.
76. Szkudelski T: The mechanism of alloxan and streptozotocin action in beta-cells of the rat pancreas. Physiol Res 2001; 50: 537-546.
77. Halliwell B, Chirico 5: Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr 199 3; 5 7: 715 S-72 5 5.
78. Chen YS, Ching Y, Liau HI, Huang GS: Assessment of the in vivo toxicity of gold nanoparticles. Nanoscale Res Lett 2009; 4: 858-864.